| US 7,553,862 B2 | ||
| 4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones | ||
| Synese Jolidon, Blauen (Switzerland); Robert Narquizian, Saint Louis (France); Roger Norcross, Olsberg (Switzerland); and Emmanuel Pinard, Linsdorf (France) | ||
| Assigned to Hoffmann-La Roche Inc., Nutley, N.J. (US) | ||
| Filed on Mar. 01, 2007, as Appl. No. 11/712,783. | ||
| Claims priority of application No. 06110812 (EP), filed on Mar. 08, 2006. | ||
| Prior Publication US 2007/0213384 A1, Sep. 13, 2007 | ||
| Int. Cl. A61K 31/4166 (2006.01); C07D 233/32 (2006.01) | ||
| U.S. Cl. 514—397 [514/398; 514/401; 548/311.1; 548/326.5] | 19 Claims |
1. A compound of formula I
 R1 is —(CH2)n-aryl or —(CH2)n-heteroaryl, wherein such groups are unsubstituted or substituted by one or more substituents selected from the group consisting
of halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkyl, cyano, nitro, —O-lower alkyl substituted by halogen
and morpholinyl;
R2 is —(CH2)n-aryl or —(CH2)n-heteroaryl, wherein such groups are unsubstituted or substituted by one or more substituents selected from the group consisting
of lower alkyl, lower alkoxy, halogen and —N(lower alkyl)2;
R3 is hydrogen or lower alkyl;
R4 is —(CH2)n-aryl or —(CH2)n-heteroaryl, wherein such groups are unsubstituted or substituted by one or more substituents selected from the group consisting
of halogen and lower alkoxy, or is lower alkyl; or
R3 and R4 form together with the N-atom to which they are attached a heterocyclic ring; and
n is 0, 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof.
|